Resources & support
Here are a few helpful links to get you started
Diabetes UK
A charity campaigning for better care, funding research, and supporting people affected with diabetes
By following the links above, you will be directed to independent websites which Sanofi has no control over. Sanofi accepts no responsibility for the content or availability of the websites.
Patient Guides - Key Safety Information
Please refer to the Patient Information leaflet and the Guide for Patients for full safety information. You may have received these materials from your doctor already.
Tzield Patient Packs
The following Tzield patient packs may have already been provided to you by your doctor or care team. If not, you have the option to view the digital guidebooks for both the paediatric and adult handbooks below.
Paediatric Patient Pack
This pack is designed with age appropriate content for ages 8-13 and their caregivers to help understand their treatment and what to expect.
Adult Patient Pack
This pack is designed for adults and their caregivers to help understand their treatment and what to expect.
Support with needle phobia1
If you are afraid or worried about needles, there are a few things you can do to help overcome your fear:
Tell the doctor or nurse who is giving you Tzield
They can answer your questions and chat to you during the infusion to distract you.
Learn an applied tension technique
If your fear is linked to fainting, or feeling faint, you can learn an applied tension technique.
Learn a breathing for relaxation exercise
If you feel panicky but not faint, you can learn a breathing for relaxation exercise.
Learn more about applied tension techniques and breathing for relaxation exercises on the NHS website here.
By following the link above, you will be directed to an independent website which Sanofi has no control over. Sanofi accepts no responsibility for the content or availability of the website.
Tzield is a medicine used to delay the start of Stage 3 Type 1 diabetes. This condition happens when the body cannot make enough insulin on its own and may need insulin injections. This medicine is used in adults and children aged 8 years and older who have Stage 2 Type 1 diabetes.2
If you have any questions on how Tzield works or about your treatment with Tzield, ask your doctor.
This website is not intended to be a substitute for medical advice. Please refer to the Patient information leaflet and the Patient Guide for full safety information. You may have received these items from your doctor already.
The contents of this website have been developed and funded by Sanofi.
References:
- NHS. Needle phobia and overcoming your fear. Available at: https://www.guysandstthomas.nhs.uk/health-information/needle-phobia-and-overcoming-your-fear. Accessed: September 2026.
- TZIELD® (teplizumab) UK Patient Information Leaflet.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store.
Alternatively, you can report side effects to Sanofi on Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com. By reporting side effects, you can help provide more information on the safety of this medicine.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
© 2026 Sanofi. All rights reserved. MAT-XU-2501108 (V2.0) | September 2026
Welcome to Tzield
Welcome to Tzield
This website and its contents have been developed by Sanofi for patients in the United Kingdom who have been prescribed Tzield.
In order to proceed into the website, please confirm that you are, or you care for, a patient in the United Kingdom prescribed Tzield by clicking the confirmation button below.
MAT-XU-2503330 (V2.0) - Date of preparation: September 2026